NeurAxis Escalates Commercial Rollout

The VA is an unexpected, lucrative revenue stream.

NeurAxis (NRXS) offers FDA-cleared treatment for patients aged 8 to 21 with functional abdominal pain associated with irritable bowel syndrome (”IBS”) and functional dyspepsia (”FD”) using its electrical nerve field stimulator (”PENFS”) technology, IB-Stim. Our investment thesis is based on the IB-Stim meeting an unmet need in the pediatric market, a ma…